TY  - JOUR
AU  - Bužančić, Iva
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Ortner Hadžiabdić, Maja
AU  - Brkić, Jovana
AU  - Fialová, Daniela
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5571
AB  - Pharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.
PB  - Nature Research
T2  - Scientific Reports
T1  - Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment
VL  - 14
IS  - 1
SP  - 6235
DO  - 10.1038/s41598-024-56780-1
ER  - 

@article{
author = "Bužančić, Iva and Držaić, Margita and Kummer, Ingrid and Ortner Hadžiabdić, Maja and Brkić, Jovana and Fialová, Daniela",
year = "2024",
abstract = "Pharmacist’s geriatric assessment can provide valuable insights into potential deprescribing targets, while including important information on various health-related domains. Data collected from a geriatric assessment questionnaire, for 388 patients, from the Croatian cohort of the EuroAgeism H2020 ESR 7 international project, along with guideline-based deprescribing criteria, were used to analyse potentially inappropriate prescribing of four medication groups (benzodiazepines (BZN), proton pump inhibitors (PPI), opioids, and non-steroidal anti-inflammatory drugs (NSAID)), and to assess the deprescribing potential. Binary logistic regression was used to explore the effects of age, gender, number of medicines and diagnoses, self-reported health, frailty score, and healthcare utilization on the likelihood of needing deprescribing. More than half of participants (n = 216, 55.2%) are candidates for deprescribing, with 31.1% of PPI, 74.8% of NSAID, 75% of opioid, and 96.1% of BZN users meeting at least one criterion. Most common criteria for deprescribing were inappropriately long use and safety concerns. Women (aOR = 2.58; p < 0.001), those reporting poor self-reported health (aOR = 5.14; p < 0.001), and those exposed to polypharmacy (aOR = 1.29; p < 0.001) had higher odds of needing to have medicines deprescribed. The high rate of deprescribing potential warrants prompt action to increase patient safety and decrease polypharmacy. Pharmacist’s geriatric assessment and deprescribing-focused medication review could be used to lead a personalised approach.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment",
volume = "14",
number = "1",
pages = "6235",
doi = "10.1038/s41598-024-56780-1"
}

Bužančić, I., Držaić, M., Kummer, I., Ortner Hadžiabdić, M., Brkić, J.,& Fialová, D.. (2024). Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment. in Scientific Reports
Nature Research., 14(1), 6235.
https://doi.org/10.1038/s41598-024-56780-1

Bužančić I, Držaić M, Kummer I, Ortner Hadžiabdić M, Brkić J, Fialová D. Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment. in Scientific Reports. 2024;14(1):6235.
doi:10.1038/s41598-024-56780-1 .

Bužančić, Iva, Držaić, Margita, Kummer, Ingrid, Ortner Hadžiabdić, Maja, Brkić, Jovana, Fialová, Daniela, "Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment" in Scientific Reports, 14, no. 1 (2024):6235,
https://doi.org/10.1038/s41598-024-56780-1 . .

TY  - JOUR
AU  - Bužančić, Iva
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Ortner Hadžiabdić, Maja
AU  - Brkić, Jovana
AU  - Fialová, Daniela
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5621
AB  - Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-56780-1, published online 14 March 2024 The original version of this Article contained an error in the Funding section. “All the research work was funded by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by the Grants: InoMed, Reg. No CZ.02.1.01/0.0/0.0/18_069/0010046, the European Horizon 2020 I-CARE4OLD Grant No 965341, START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551 Grant and Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Therapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.” now reads: “Publication of this work was supported by the I-CARE4OLD project that has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No. 96534. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. More information on the I-CARE4OLD project can be found at http://www.icare4old.eu and https://cordis.europa.eu/project/id/965341. Except secondary analyses and works on the publication, data collection and teamwork were funded also by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by grants: START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551, Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Terapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607.” The original Article has been corrected.
PB  - Nature Research
T2  - Scientific Reports
T1  - Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1)
VL  - 14
IS  - 1
DO  - 10.1038/s41598-024-60073-y
ER  - 

@article{
author = "Bužančić, Iva and Držaić, Margita and Kummer, Ingrid and Ortner Hadžiabdić, Maja and Brkić, Jovana and Fialová, Daniela",
year = "2024",
abstract = "Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-56780-1, published online 14 March 2024 The original version of this Article contained an error in the Funding section. “All the research work was funded by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by the Grants: InoMed, Reg. No CZ.02.1.01/0.0/0.0/18_069/0010046, the European Horizon 2020 I-CARE4OLD Grant No 965341, START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551 Grant and Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Therapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.” now reads: “Publication of this work was supported by the I-CARE4OLD project that has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No. 96534. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. More information on the I-CARE4OLD project can be found at http://www.icare4old.eu and https://cordis.europa.eu/project/id/965341. Except secondary analyses and works on the publication, data collection and teamwork were funded also by the EuroAgeism H2020 project (ESR7 project), supported by the European Union research and innovation program under the Grant Agreement of the Marie Skłodowska-Curie Foundation Number MSCF-ITN-764632. Research works of Assoc. Prof. Daniela Fialová, PharmD, Ph.D. and members of her research team were supported by grants: START/MED/093 EN.02.2.69/0.0/0.0/19_073/0016935, SVV 260 551, Cooperatio research program of the Faculty of Pharmacy, Charles University (Research Unit: “Ageing, Polypharmacotherapy and Changes in Terapeutic Value of Drugs in the Aged’’, KSKF-I.), and NETPHARM project CZ.02.01.01/00/22_008/0004607.” The original Article has been corrected.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1)",
volume = "14",
number = "1",
doi = "10.1038/s41598-024-60073-y"
}

Bužančić, I., Držaić, M., Kummer, I., Ortner Hadžiabdić, M., Brkić, J.,& Fialová, D.. (2024). Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1). in Scientific Reports
Nature Research., 14(1).
https://doi.org/10.1038/s41598-024-60073-y

Bužančić I, Držaić M, Kummer I, Ortner Hadžiabdić M, Brkić J, Fialová D. Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1). in Scientific Reports. 2024;14(1).
doi:10.1038/s41598-024-60073-y .

Bužančić, Iva, Držaić, Margita, Kummer, Ingrid, Ortner Hadžiabdić, Maja, Brkić, Jovana, Fialová, Daniela, "Correction to: Deprescribing potential of commonly used medications among community-dwelling older adults: insights from a pharmacist’s geriatric assessment (Scientific Reports, (2024), 14, 1, (6235), 10.1038/s41598-024-56780-1)" in Scientific Reports, 14, no. 1 (2024),
https://doi.org/10.1038/s41598-024-60073-y . .

TY  - JOUR
AU  - Bužančić, Iva
AU  - Belec, Dora
AU  - Držaić, Margita
AU  - Kummer, Ingrid
AU  - Brkić, Jovana
AU  - Fialová, Daniela
AU  - Ortner Hadžiabdić, Maja
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5344
AB  - Aims: The aim of this study was to compare the clinical decision-making for benzodiazepine deprescribing between a healthcare provider (HCP) and an artificial intelligence (AI) chatbot GPT4 (ChatGPT-4). Methods: We analysed real-world data from a Croatian cohort of community-dwelling benzodiazepine patients (n = 154) within the EuroAgeism H2020 ESR 7 project. HCPs evaluated the data using pre-established deprescribing criteria to assess benzodiazepine discontinuation potential. The research team devised and tested AI prompts to ensure consistency with HCP judgements. An independent researcher employed ChatGPT-4 with predetermined prompts to simulate clinical decisions for each patient case. Data derived from human-HCP and ChatGPT-4 decisions were compared for agreement rates and Cohen's kappa. 
Results : Both HPC and ChatGPT identified patients for benzodiazepine deprescribing (96.1% and 89.6%, respectively), showing an agreement rate of 95% (κ=.200,P=.012). Agreement on four deprescribing criteria ranged from 74.7% to 91.3%(lack of indicationκ=.352,P< .001; prolonged useκ=.088,P=.280; safety concernsκ=.123,P=.006; incorrect dosageκ=.264,P=.001). Important limitationsof GPT-4 responses were identified, including 22.1% ambiguous outputs, genericanswers and inaccuracies, posing inappropriate decision-making risks.Conclusions : While AI-HCP agreement is substantial, sole AI reliance poses a risk forunsuitable clinical decision-making. This study's findings reveal both strengths andareas for enhancement of ChatGPT-4 in the deprescribing recommendations within areal-world sample. Our study underscores the need for additional research on chatbot functionality in patient therapy decision-making, further fostering the advance-ment of AI for optimal performance.
PB  - John Wiley and Sons Inc
T2  - British Journal of Clinical Pharmacology
T1  - Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach
VL  - 90
IS  - 3
SP  - 662
EP  - 674
DO  - 10.1111/bcp.15963
ER  - 

@article{
author = "Bužančić, Iva and Belec, Dora and Držaić, Margita and Kummer, Ingrid and Brkić, Jovana and Fialová, Daniela and Ortner Hadžiabdić, Maja",
year = "2024",
abstract = "Aims: The aim of this study was to compare the clinical decision-making for benzodiazepine deprescribing between a healthcare provider (HCP) and an artificial intelligence (AI) chatbot GPT4 (ChatGPT-4). Methods: We analysed real-world data from a Croatian cohort of community-dwelling benzodiazepine patients (n = 154) within the EuroAgeism H2020 ESR 7 project. HCPs evaluated the data using pre-established deprescribing criteria to assess benzodiazepine discontinuation potential. The research team devised and tested AI prompts to ensure consistency with HCP judgements. An independent researcher employed ChatGPT-4 with predetermined prompts to simulate clinical decisions for each patient case. Data derived from human-HCP and ChatGPT-4 decisions were compared for agreement rates and Cohen's kappa. 
Results : Both HPC and ChatGPT identified patients for benzodiazepine deprescribing (96.1% and 89.6%, respectively), showing an agreement rate of 95% (κ=.200,P=.012). Agreement on four deprescribing criteria ranged from 74.7% to 91.3%(lack of indicationκ=.352,P< .001; prolonged useκ=.088,P=.280; safety concernsκ=.123,P=.006; incorrect dosageκ=.264,P=.001). Important limitationsof GPT-4 responses were identified, including 22.1% ambiguous outputs, genericanswers and inaccuracies, posing inappropriate decision-making risks.Conclusions : While AI-HCP agreement is substantial, sole AI reliance poses a risk forunsuitable clinical decision-making. This study's findings reveal both strengths andareas for enhancement of ChatGPT-4 in the deprescribing recommendations within areal-world sample. Our study underscores the need for additional research on chatbot functionality in patient therapy decision-making, further fostering the advance-ment of AI for optimal performance.",
publisher = "John Wiley and Sons Inc",
journal = "British Journal of Clinical Pharmacology",
title = "Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach",
volume = "90",
number = "3",
pages = "662-674",
doi = "10.1111/bcp.15963"
}

Bužančić, I., Belec, D., Držaić, M., Kummer, I., Brkić, J., Fialová, D.,& Ortner Hadžiabdić, M.. (2024). Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach. in British Journal of Clinical Pharmacology
John Wiley and Sons Inc., 90(3), 662-674.
https://doi.org/10.1111/bcp.15963

Bužančić I, Belec D, Držaić M, Kummer I, Brkić J, Fialová D, Ortner Hadžiabdić M. Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach. in British Journal of Clinical Pharmacology. 2024;90(3):662-674.
doi:10.1111/bcp.15963 .

Bužančić, Iva, Belec, Dora, Držaić, Margita, Kummer, Ingrid, Brkić, Jovana, Fialová, Daniela, Ortner Hadžiabdić, Maja, "Clinical decision-making in benzodiazepine deprescribing by healthcare providers vs. AI-assisted approach" in British Journal of Clinical Pharmacology, 90, no. 3 (2024):662-674,
https://doi.org/10.1111/bcp.15963 . .

TY  - JOUR
AU  - Lukačišinová, Anna
AU  - Reissigová, Jindra
AU  - Ortner-Hadžiabdić, Maja
AU  - Brkić, Jovana
AU  - Okuyan, Betul
AU  - Volmer, Daisy
AU  - Tadić, Ivana
AU  - Modamio, Pilar
AU  - Mariño, Eduardo
AU  - Tachkov, Konstantine
AU  - Liperotti, Rosa
AU  - Onder, Graziano
AU  - Finne-Soveri, Harriet
AU  - van Hout, Hein
AU  - Howard, Elizabeth P.
AU  - Fialová, Daniela
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5563
AB  - Background: The use of benzodiazepines (BZDs) in older population is often accompanied by drug-related complications. Inappropriate BZD use significantly alters older adults’ clinical and functional status. This study compares the prevalence, prescribing patterns and factors associated with BZD use in community-dwelling older patients in 7 European countries. Methods: International, cross-sectional study was conducted in community-dwelling older adults (65 +) in the Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain between Feb2019 and Mar2020. Structured and standardized questionnaire based on interRAI assessment scales was applied. Logistic regression was used to evaluate factors associated with BZD use. Results: Out of 2,865 older patients (mean age 73.2 years ± 6.8, 61.2% women) 14.9% were BZD users. The highest prevalence of BZD use was identified in Croatia (35.5%), Spain (33.5%) and Serbia (31.3%). The most frequently prescribed BZDs were diazepam (27.9% of 426 BZD users), alprazolam (23.7%), bromazepam (22.8%) and lorazepam (16.7%). Independent factors associated with BZD use were female gender (OR 1.58, 95%CI 1.19–2.10), hyperpolypharmacy (OR 1.97, 95%CI 1.22–3.16), anxiety (OR 4.26, 95%CI 2.86–6.38), sleeping problems (OR 4.47, 95%CI 3.38–5.92), depression (OR 1.95, 95%CI 1.29–2.95), repetitive anxious complaints (OR 1.77, 95%CI 1.29–2.42), problems with syncope (OR 1.78, 95%CI 1.03–3.06), and loss of appetite (OR 0.60, 95%CI 0.38–0.94). In comparison to Croatia, residing in other countries was associated with lower odds of BZD use (ORs varied from 0.49 (95%CI 0.32–0.75) in Spain to 0.01 (95%CI 0.00–0.03) in Turkey), excluding Serbia (OR 1.11, 95%CI 0.79–1.56). Conclusions: Despite well-known negative effects, BZDs are still frequently prescribed in older outpatient population in European countries. Principles of safer geriatric prescribing and effective deprescribing strategies should be individually applied in older BZD users.
PB  - BioMed Central Ltd
T2  - BMC Geriatrics
T1  - Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries
VL  - 24
IS  - 1
DO  - 10.1186/s12877-024-04742-7
ER  - 

@article{
author = "Lukačišinová, Anna and Reissigová, Jindra and Ortner-Hadžiabdić, Maja and Brkić, Jovana and Okuyan, Betul and Volmer, Daisy and Tadić, Ivana and Modamio, Pilar and Mariño, Eduardo and Tachkov, Konstantine and Liperotti, Rosa and Onder, Graziano and Finne-Soveri, Harriet and van Hout, Hein and Howard, Elizabeth P. and Fialová, Daniela",
year = "2024",
abstract = "Background: The use of benzodiazepines (BZDs) in older population is often accompanied by drug-related complications. Inappropriate BZD use significantly alters older adults’ clinical and functional status. This study compares the prevalence, prescribing patterns and factors associated with BZD use in community-dwelling older patients in 7 European countries. Methods: International, cross-sectional study was conducted in community-dwelling older adults (65 +) in the Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain between Feb2019 and Mar2020. Structured and standardized questionnaire based on interRAI assessment scales was applied. Logistic regression was used to evaluate factors associated with BZD use. Results: Out of 2,865 older patients (mean age 73.2 years ± 6.8, 61.2% women) 14.9% were BZD users. The highest prevalence of BZD use was identified in Croatia (35.5%), Spain (33.5%) and Serbia (31.3%). The most frequently prescribed BZDs were diazepam (27.9% of 426 BZD users), alprazolam (23.7%), bromazepam (22.8%) and lorazepam (16.7%). Independent factors associated with BZD use were female gender (OR 1.58, 95%CI 1.19–2.10), hyperpolypharmacy (OR 1.97, 95%CI 1.22–3.16), anxiety (OR 4.26, 95%CI 2.86–6.38), sleeping problems (OR 4.47, 95%CI 3.38–5.92), depression (OR 1.95, 95%CI 1.29–2.95), repetitive anxious complaints (OR 1.77, 95%CI 1.29–2.42), problems with syncope (OR 1.78, 95%CI 1.03–3.06), and loss of appetite (OR 0.60, 95%CI 0.38–0.94). In comparison to Croatia, residing in other countries was associated with lower odds of BZD use (ORs varied from 0.49 (95%CI 0.32–0.75) in Spain to 0.01 (95%CI 0.00–0.03) in Turkey), excluding Serbia (OR 1.11, 95%CI 0.79–1.56). Conclusions: Despite well-known negative effects, BZDs are still frequently prescribed in older outpatient population in European countries. Principles of safer geriatric prescribing and effective deprescribing strategies should be individually applied in older BZD users.",
publisher = "BioMed Central Ltd",
journal = "BMC Geriatrics",
title = "Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries",
volume = "24",
number = "1",
doi = "10.1186/s12877-024-04742-7"
}

Lukačišinová, A., Reissigová, J., Ortner-Hadžiabdić, M., Brkić, J., Okuyan, B., Volmer, D., Tadić, I., Modamio, P., Mariño, E., Tachkov, K., Liperotti, R., Onder, G., Finne-Soveri, H., van Hout, H., Howard, E. P.,& Fialová, D.. (2024). Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries. in BMC Geriatrics
BioMed Central Ltd., 24(1).
https://doi.org/10.1186/s12877-024-04742-7

Lukačišinová A, Reissigová J, Ortner-Hadžiabdić M, Brkić J, Okuyan B, Volmer D, Tadić I, Modamio P, Mariño E, Tachkov K, Liperotti R, Onder G, Finne-Soveri H, van Hout H, Howard EP, Fialová D. Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries. in BMC Geriatrics. 2024;24(1).
doi:10.1186/s12877-024-04742-7 .

Lukačišinová, Anna, Reissigová, Jindra, Ortner-Hadžiabdić, Maja, Brkić, Jovana, Okuyan, Betul, Volmer, Daisy, Tadić, Ivana, Modamio, Pilar, Mariño, Eduardo, Tachkov, Konstantine, Liperotti, Rosa, Onder, Graziano, Finne-Soveri, Harriet, van Hout, Hein, Howard, Elizabeth P., Fialová, Daniela, "Prevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries" in BMC Geriatrics, 24, no. 1 (2024),
https://doi.org/10.1186/s12877-024-04742-7 . .

TY  - JOUR
AU  - Guntschnig, Sonja
AU  - Antoniadis, Vasilis
AU  - Falamic, Slaven
AU  - Kovačević, Tijana
AU  - Kurczewska-Michalak, Marta
AU  - Miljković, Branislava
AU  - Olearova, Anna
AU  - Sviestina, Inese
AU  - Szucs, Attila
AU  - Bampali, Konstantina
AU  - Tiszai, Zita
AU  - Volmer, Daisy
AU  - Wiela-Hojeńska, Anna
AU  - Fialová, Daniela
AU  - Vlcek, Jiri
AU  - Stuhec, Matej
AU  - Hogg, Anita
AU  - Scott, Michael
AU  - Stewart, Derek
AU  - Mair, Alpana
AU  - Ravera, Silvia
AU  - Lery, François-Xavier
AU  - Kardas, Przemysław
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4984
AB  - Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.
PB  - Frontiers Media SA
T2  - Frontiers in Pharmacology
T1  - Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes
VL  - 14
DO  - 10.3389/fphar.2023.1244151
ER  - 

@article{
author = "Guntschnig, Sonja and Antoniadis, Vasilis and Falamic, Slaven and Kovačević, Tijana and Kurczewska-Michalak, Marta and Miljković, Branislava and Olearova, Anna and Sviestina, Inese and Szucs, Attila and Bampali, Konstantina and Tiszai, Zita and Volmer, Daisy and Wiela-Hojeńska, Anna and Fialová, Daniela and Vlcek, Jiri and Stuhec, Matej and Hogg, Anita and Scott, Michael and Stewart, Derek and Mair, Alpana and Ravera, Silvia and Lery, François-Xavier and Kardas, Przemysław",
year = "2023",
abstract = "Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.",
publisher = "Frontiers Media SA",
journal = "Frontiers in Pharmacology",
title = "Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes",
volume = "14",
doi = "10.3389/fphar.2023.1244151"
}

Guntschnig, S., Antoniadis, V., Falamic, S., Kovačević, T., Kurczewska-Michalak, M., Miljković, B., Olearova, A., Sviestina, I., Szucs, A., Bampali, K., Tiszai, Z., Volmer, D., Wiela-Hojeńska, A., Fialová, D., Vlcek, J., Stuhec, M., Hogg, A., Scott, M., Stewart, D., Mair, A., Ravera, S., Lery, F.,& Kardas, P.. (2023). Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. in Frontiers in Pharmacology
Frontiers Media SA., 14.
https://doi.org/10.3389/fphar.2023.1244151

Guntschnig S, Antoniadis V, Falamic S, Kovačević T, Kurczewska-Michalak M, Miljković B, Olearova A, Sviestina I, Szucs A, Bampali K, Tiszai Z, Volmer D, Wiela-Hojeńska A, Fialová D, Vlcek J, Stuhec M, Hogg A, Scott M, Stewart D, Mair A, Ravera S, Lery F, Kardas P. Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. in Frontiers in Pharmacology. 2023;14.
doi:10.3389/fphar.2023.1244151 .

Guntschnig, Sonja, Antoniadis, Vasilis, Falamic, Slaven, Kovačević, Tijana, Kurczewska-Michalak, Marta, Miljković, Branislava, Olearova, Anna, Sviestina, Inese, Szucs, Attila, Bampali, Konstantina, Tiszai, Zita, Volmer, Daisy, Wiela-Hojeńska, Anna, Fialová, Daniela, Vlcek, Jiri, Stuhec, Matej, Hogg, Anita, Scott, Michael, Stewart, Derek, Mair, Alpana, Ravera, Silvia, Lery, François-Xavier, Kardas, Przemysław, "Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes" in Frontiers in Pharmacology, 14 (2023),
https://doi.org/10.3389/fphar.2023.1244151 . .

TY  - JOUR
AU  - Brkić, Jovana
AU  - Fialová, Daniela
AU  - Okuyan, Betul
AU  - Kummer, Ingrid
AU  - Šesto, Sofija
AU  - Capiau, Andreas
AU  - Ortner Hadžiabdić, Maja
AU  - Tachkov, Konstantin
AU  - Bobrova, Veera
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4345
PB  - Nature Research
T2  - Scientific Reports
T1  - Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis
VL  - 12
IS  - 1
DO  - 10.1038/s41598-022-25155-9
ER  - 

@article{
author = "Brkić, Jovana and Fialová, Daniela and Okuyan, Betul and Kummer, Ingrid and Šesto, Sofija and Capiau, Andreas and Ortner Hadžiabdić, Maja and Tachkov, Konstantin and Bobrova, Veera",
year = "2022",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis",
volume = "12",
number = "1",
doi = "10.1038/s41598-022-25155-9"
}

Brkić, J., Fialová, D., Okuyan, B., Kummer, I., Šesto, S., Capiau, A., Ortner Hadžiabdić, M., Tachkov, K.,& Bobrova, V.. (2022). Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis. in Scientific Reports
Nature Research., 12(1).
https://doi.org/10.1038/s41598-022-25155-9

Brkić J, Fialová D, Okuyan B, Kummer I, Šesto S, Capiau A, Ortner Hadžiabdić M, Tachkov K, Bobrova V. Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis. in Scientific Reports. 2022;12(1).
doi:10.1038/s41598-022-25155-9 .

Brkić, Jovana, Fialová, Daniela, Okuyan, Betul, Kummer, Ingrid, Šesto, Sofija, Capiau, Andreas, Ortner Hadžiabdić, Maja, Tachkov, Konstantin, Bobrova, Veera, "Author Correction: Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta‑analysis" in Scientific Reports, 12, no. 1 (2022),
https://doi.org/10.1038/s41598-022-25155-9 . .

TY  - JOUR
AU  - Brkić, Jovana
AU  - Fialová, Daniela
AU  - Okuyan, Betul
AU  - Kummer, Ingrid
AU  - Šesto, Sofija
AU  - Capiau, Andreas
AU  - Ortner Hadžiabdić, Maja
AU  - Tachkov, Konstantin
AU  - Bobrova, Veera
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4286
AB  - We aimed to systematically review the prevalence of potentially inappropriate prescribing (PIP) in older adults in Central and Eastern Europe (CEE) in all care settings. We searched Embase and MEDLINE (up to June 2019) and checked the reference lists of the included studies and relevant reviews. Eligible studies used validated explicit or implicit tools to assess the PIP prevalence in older adults in CEE. All study designs were considered, except case‒control studies and case series. We assessed the risk of bias using the Joanna Briggs Institute Prevalence Critical Appraisal Tool and the certainty of evidence using the GRADE approach. Meta-analysis was inappropriate due to heterogeneity in the outcome measurements. Therefore, we used the synthesis without meta-analysis approach—summarizing effect estimates method. This review included twenty-seven studies with 139,693 participants. Most studies were cross-sectional and conducted in high-income countries. The data synthesis across 26 studies revealed the PIP prevalence: the median was 34.6%, the interquartile range was 25.9–63.2%, and the range was 6.5–95.8%. The certainty of this evidence was very low due to the risk of bias, imprecision, and inconsistency. These findings show that PIP is a prevalent issue in the CEE region. Further well-designed studies conducted across countries are needed to strengthen the existing evidence and increase the generalizability of findings.
PB  - Nature Research
T2  - Scientific Reports
T1  - Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis
VL  - 12
IS  - 1
DO  - 10.1038/s41598-022-19860-8
ER  - 

@article{
author = "Brkić, Jovana and Fialová, Daniela and Okuyan, Betul and Kummer, Ingrid and Šesto, Sofija and Capiau, Andreas and Ortner Hadžiabdić, Maja and Tachkov, Konstantin and Bobrova, Veera",
year = "2022",
abstract = "We aimed to systematically review the prevalence of potentially inappropriate prescribing (PIP) in older adults in Central and Eastern Europe (CEE) in all care settings. We searched Embase and MEDLINE (up to June 2019) and checked the reference lists of the included studies and relevant reviews. Eligible studies used validated explicit or implicit tools to assess the PIP prevalence in older adults in CEE. All study designs were considered, except case‒control studies and case series. We assessed the risk of bias using the Joanna Briggs Institute Prevalence Critical Appraisal Tool and the certainty of evidence using the GRADE approach. Meta-analysis was inappropriate due to heterogeneity in the outcome measurements. Therefore, we used the synthesis without meta-analysis approach—summarizing effect estimates method. This review included twenty-seven studies with 139,693 participants. Most studies were cross-sectional and conducted in high-income countries. The data synthesis across 26 studies revealed the PIP prevalence: the median was 34.6%, the interquartile range was 25.9–63.2%, and the range was 6.5–95.8%. The certainty of this evidence was very low due to the risk of bias, imprecision, and inconsistency. These findings show that PIP is a prevalent issue in the CEE region. Further well-designed studies conducted across countries are needed to strengthen the existing evidence and increase the generalizability of findings.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis",
volume = "12",
number = "1",
doi = "10.1038/s41598-022-19860-8"
}

Brkić, J., Fialová, D., Okuyan, B., Kummer, I., Šesto, S., Capiau, A., Ortner Hadžiabdić, M., Tachkov, K.,& Bobrova, V.. (2022). Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis. in Scientific Reports
Nature Research., 12(1).
https://doi.org/10.1038/s41598-022-19860-8

Brkić J, Fialová D, Okuyan B, Kummer I, Šesto S, Capiau A, Ortner Hadžiabdić M, Tachkov K, Bobrova V. Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis. in Scientific Reports. 2022;12(1).
doi:10.1038/s41598-022-19860-8 .

Brkić, Jovana, Fialová, Daniela, Okuyan, Betul, Kummer, Ingrid, Šesto, Sofija, Capiau, Andreas, Ortner Hadžiabdić, Maja, Tachkov, Konstantin, Bobrova, Veera, "Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis" in Scientific Reports, 12, no. 1 (2022),
https://doi.org/10.1038/s41598-022-19860-8 . .

TY  - CONF
AU  - Šesto, Sofija
AU  - Tadić, Ivana
AU  - Marinković, Valentina
AU  - Odalović, Marina
AU  - Tasić, Ljiljana
AU  - Brkić, Jovana
AU  - Fialová, Daniela
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4356
PB  - Springer
C3  - International Journal of Clinical Pharmacy
T1  - Self-reported medication adherence in older patients
VL  - 43
IS  - 3
SP  - 814
EP  - 815
DO  - 10.1007/s11096-021-01279-2
ER  - 

@conference{
author = "Šesto, Sofija and Tadić, Ivana and Marinković, Valentina and Odalović, Marina and Tasić, Ljiljana and Brkić, Jovana and Fialová, Daniela",
year = "2021",
publisher = "Springer",
journal = "International Journal of Clinical Pharmacy",
title = "Self-reported medication adherence in older patients",
volume = "43",
number = "3",
pages = "814-815",
doi = "10.1007/s11096-021-01279-2"
}

Šesto, S., Tadić, I., Marinković, V., Odalović, M., Tasić, L., Brkić, J.,& Fialová, D.. (2021). Self-reported medication adherence in older patients. in International Journal of Clinical Pharmacy
Springer., 43(3), 814-815.
https://doi.org/10.1007/s11096-021-01279-2

Šesto S, Tadić I, Marinković V, Odalović M, Tasić L, Brkić J, Fialová D. Self-reported medication adherence in older patients. in International Journal of Clinical Pharmacy. 2021;43(3):814-815.
doi:10.1007/s11096-021-01279-2 .

Šesto, Sofija, Tadić, Ivana, Marinković, Valentina, Odalović, Marina, Tasić, Ljiljana, Brkić, Jovana, Fialová, Daniela, "Self-reported medication adherence in older patients" in International Journal of Clinical Pharmacy, 43, no. 3 (2021):814-815,
https://doi.org/10.1007/s11096-021-01279-2 . .

TY  - JOUR
AU  - Fialová, Daniela
AU  - Laffon, Blanca
AU  - Marinković, Valentina
AU  - Tasić, Ljiljana
AU  - Doro, Peter
AU  - Soos, Gyongyver
AU  - Mota, Jorge
AU  - Dogan, Soner
AU  - Brkić, Jovana
AU  - Teixeira, Joao Paulo
AU  - Valdiglesias, Vanessa
AU  - Costa, Solange
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3360
AB  - IntroductionThe importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the age-blind approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches.MethodologyA narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise).ResultsOlder patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of somenonpharmacological strategies is highly underestimated in older adultsin contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinicalstudies.ConclusionSeveral regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat
VL  - 75
IS  - 4
SP  - 451
EP  - 466
DO  - 10.1007/s00228-018-2603-5
ER  - 

@article{
author = "Fialová, Daniela and Laffon, Blanca and Marinković, Valentina and Tasić, Ljiljana and Doro, Peter and Soos, Gyongyver and Mota, Jorge and Dogan, Soner and Brkić, Jovana and Teixeira, Joao Paulo and Valdiglesias, Vanessa and Costa, Solange",
year = "2019",
abstract = "IntroductionThe importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the age-blind approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches.MethodologyA narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise).ResultsOlder patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of somenonpharmacological strategies is highly underestimated in older adultsin contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinicalstudies.ConclusionSeveral regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat",
volume = "75",
number = "4",
pages = "451-466",
doi = "10.1007/s00228-018-2603-5"
}

Fialová, D., Laffon, B., Marinković, V., Tasić, L., Doro, P., Soos, G., Mota, J., Dogan, S., Brkić, J., Teixeira, J. P., Valdiglesias, V.,& Costa, S.. (2019). Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 75(4), 451-466.
https://doi.org/10.1007/s00228-018-2603-5

Fialová D, Laffon B, Marinković V, Tasić L, Doro P, Soos G, Mota J, Dogan S, Brkić J, Teixeira JP, Valdiglesias V, Costa S. Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat. in European Journal of Clinical Pharmacology. 2019;75(4):451-466.
doi:10.1007/s00228-018-2603-5 .

Fialová, Daniela, Laffon, Blanca, Marinković, Valentina, Tasić, Ljiljana, Doro, Peter, Soos, Gyongyver, Mota, Jorge, Dogan, Soner, Brkić, Jovana, Teixeira, Joao Paulo, Valdiglesias, Vanessa, Costa, Solange, "Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat" in European Journal of Clinical Pharmacology, 75, no. 4 (2019):451-466,
https://doi.org/10.1007/s00228-018-2603-5 . .

TY  - JOUR
AU  - Fialová, Daniela
AU  - Brkić, Jovana
AU  - Laffon, Blanca
AU  - Reissigova, Jindra
AU  - Gresakova, Silvia
AU  - Dogan, Soner
AU  - Doro, Peter
AU  - Tasić, Ljiljana
AU  - Marinković, Valentina
AU  - Valdiglesias, Vanessa
AU  - Costa, Solange
AU  - Kostriba, Jan
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3264
AB  - Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.
PB  - Sage Publications Ltd, London
T2  - Therapeutic Advances in Drug Safet
T1  - Applicability of EU(7)-PIM criteria in cross-national studies in European countries
VL  - 10
DO  - 10.1177/2042098619854014
ER  - 

@article{
author = "Fialová, Daniela and Brkić, Jovana and Laffon, Blanca and Reissigova, Jindra and Gresakova, Silvia and Dogan, Soner and Doro, Peter and Tasić, Ljiljana and Marinković, Valentina and Valdiglesias, Vanessa and Costa, Solange and Kostriba, Jan",
year = "2019",
abstract = "Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.",
publisher = "Sage Publications Ltd, London",
journal = "Therapeutic Advances in Drug Safet",
title = "Applicability of EU(7)-PIM criteria in cross-national studies in European countries",
volume = "10",
doi = "10.1177/2042098619854014"
}

Fialová, D., Brkić, J., Laffon, B., Reissigova, J., Gresakova, S., Dogan, S., Doro, P., Tasić, L., Marinković, V., Valdiglesias, V., Costa, S.,& Kostriba, J.. (2019). Applicability of EU(7)-PIM criteria in cross-national studies in European countries. in Therapeutic Advances in Drug Safet
Sage Publications Ltd, London., 10.
https://doi.org/10.1177/2042098619854014

Fialová D, Brkić J, Laffon B, Reissigova J, Gresakova S, Dogan S, Doro P, Tasić L, Marinković V, Valdiglesias V, Costa S, Kostriba J. Applicability of EU(7)-PIM criteria in cross-national studies in European countries. in Therapeutic Advances in Drug Safet. 2019;10.
doi:10.1177/2042098619854014 .

Fialová, Daniela, Brkić, Jovana, Laffon, Blanca, Reissigova, Jindra, Gresakova, Silvia, Dogan, Soner, Doro, Peter, Tasić, Ljiljana, Marinković, Valentina, Valdiglesias, Vanessa, Costa, Solange, Kostriba, Jan, "Applicability of EU(7)-PIM criteria in cross-national studies in European countries" in Therapeutic Advances in Drug Safet, 10 (2019),
https://doi.org/10.1177/2042098619854014 . .

TY  - CONF
AU  - Fialová, Daniela
AU  - Vysinova, Tereza
AU  - Gresakova, Silvia
AU  - Laffon-Deusdad, Blanca
AU  - Doro, Peter
AU  - Dogan, Soner
AU  - Costa, Solange
AU  - Valdiglesias, Vanessa
AU  - Brkić, Jovana
AU  - Marinković, Valentina
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2950
PB  - Springer, Dordrecht
C3  - International Journal of Clinical Pharmacy
T1  - Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative
VL  - 39
IS  - 1
SP  - 310
EP  - 311
DO  - 10.1007/s11096-016-0404-4
ER  - 

@conference{
author = "Fialová, Daniela and Vysinova, Tereza and Gresakova, Silvia and Laffon-Deusdad, Blanca and Doro, Peter and Dogan, Soner and Costa, Solange and Valdiglesias, Vanessa and Brkić, Jovana and Marinković, Valentina",
year = "2017",
publisher = "Springer, Dordrecht",
journal = "International Journal of Clinical Pharmacy",
title = "Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative",
volume = "39",
number = "1",
pages = "310-311",
doi = "10.1007/s11096-016-0404-4"
}

Fialová, D., Vysinova, T., Gresakova, S., Laffon-Deusdad, B., Doro, P., Dogan, S., Costa, S., Valdiglesias, V., Brkić, J.,& Marinković, V.. (2017). Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative. in International Journal of Clinical Pharmacy
Springer, Dordrecht., 39(1), 310-311.
https://doi.org/10.1007/s11096-016-0404-4

Fialová D, Vysinova T, Gresakova S, Laffon-Deusdad B, Doro P, Dogan S, Costa S, Valdiglesias V, Brkić J, Marinković V. Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative. in International Journal of Clinical Pharmacy. 2017;39(1):310-311.
doi:10.1007/s11096-016-0404-4 .

Fialová, Daniela, Vysinova, Tereza, Gresakova, Silvia, Laffon-Deusdad, Blanca, Doro, Peter, Dogan, Soner, Costa, Solange, Valdiglesias, Vanessa, Brkić, Jovana, Marinković, Valentina, "Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative" in International Journal of Clinical Pharmacy, 39, no. 1 (2017):310-311,
https://doi.org/10.1007/s11096-016-0404-4 . .